MIB Agents Osteosarcoma Alliance

Leading pediatric Osteosarcoma nonprofit dedicated to 'Making It Better' for the Osteosarcoma community🎗

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by Michelle Choe, MD on OsteoBites to discuss, “A Phase 1 Trial evaluating Folate Receptor Alpha CAR T cells for Advanced Osteosarcoma”.

Watch the full episode here: https://t.co/K11Nvv8tSR

#MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Happy to chat with @Philanthropy on current state of affairs. Grateful for all who support better for kids with cancer.

[The Chronicle of Philanthropy @Philanthropy]

Year-end giving is growing lopsided. Ann Graham, CEO of @AgentsMIB, says the split is stark: "90 percent of the donations that come in are funded by 10 percent...What's shrinking is the 90 percent who are really concerned about filling their car up with gas or getting groceries." More:

Read more: https://t.co/1VS9hrFn2S

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by Katharine Offer, MD on OsteoBites.

Watch the full episode here: https://t.co/QC0WR0qjeg

#MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

@BuiltFromIt Thank you @BarrySilbert for the shout out 💫🎗️💛! @AgentsMIB Makes it Better for kids with the oldest known cancer, #osteosarcoma through research, programs, & education. https://t.co/aKlxJaJVLU.

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

@BuiltFromIt Thank you for recognizing the great divide in childhood cancers and adult cancers! Adult cancers get 96% of government funding (essential for clinical trials), childhood cancers, of which there are over 300. Funding kids cancers nets avg 72 years more life. Fund kids cancer!

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by W. Thomas Cash on OsteoBites to discuss, “A Phase 1b Study of Tegavivint, a TBL1 Inhibitor, with Gemcitabine in Patients with Relapsed or Refractory Osteosarcoma (TIGER)”.

Watch the full episode here: https://t.co/aYTlDcky7l

#MIBAgents #MakeItBetter

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by Subhashini Jagu, PhD (CCDI) on OsteoBites to discuss, “CCDI Data Ecosystem in Action: Enabling Data-Driven Discovery”.

Watch the full episode here: https://t.co/3CsXAJm1Q4

#MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by Ed Greenfield, PhD on OsteoBites to discuss, “Functional Precision Medicine for Osteosarcoma”.

Watch the full episode here: https://t.co/uXQGo1Dzwe

#MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

We are so proud of MIB Agents’ Junior Advisory Board member Sabina on her recent CNN feature and album release!

A special thank you to CNN, Dr. Sanjay Gupta, Sabina’s family and Caleb Hellerman for helping to Make It Better!

#MIBAgents #MakeItBetter #osteosarcoma #CNN

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by Marta Roman Moreno, PhD (Because of Charlotte) on OsteoBites to discuss, “Dissecting and Targeting Metastatic Drivers in Osteosarcoma”

Watch the full episode here: https://t.co/WGt0bKS2ga

#MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday we were joined by Alexander Davies, DVM, PhD on OsteoBites to discuss, “Validation of MCL1 inhibition and combinatorial therapy for elimination of osteosarcoma lung metastasis”.

Watch the full episode here: https://t.co/0BkAin1LjB

#MIBAgents #MakeItBetter #Osteosarcoma

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by Jeremy Rosenblum, MD, on OsteoBites to discuss, “Combinatorial immunotherapy to overcome cellular therapy resistance in osteosarcoma”.

Watch the full episode here: https://t.co/IFVPt5xW7y

#MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by Barbara VanHare on OsteoBites to discuss, "Your Story, Your Tissue, Your Impact: Changing the Future of Osteosarcoma".

Watch the full episode here: https://t.co/ori0X5MBhT

#MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by Matteo Trucco, MD on OsteoBites to discuss, "A Guide to FACTOR 2026 Scientific Panels".

Watch the full episode here: https://t.co/ilTDRmIwoT

#MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast #F26 #FACTOR2026 #FACTOR

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

@SweetCorderoLab @DrBetsYoung @AegeanConf Yay @DrBetsYoung - cheering for you as always!

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by Andrew Clugston, PhD on OsteoBites to discuss, "Defining tumor-specific vulnerabilities by mapping oncogenic structural variation in osteosarcoma".

Watch the full episode here: https://t.co/LD1yY2fBcO

#MIBAgents #MakeItBetter #osteosarcoma

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by Caroline Maloney, MD, PhD on OsteoBites to discuss, "Targeting Perioperative Myeloid Responses Through NOD/RIPK2 Modulation to Prevent Metastatic Progression in Osteosarcoma".

Watch the full episode here: https://t.co/wEKB2YTA5C

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by Philippos Costa, MD on OsteoBites to dicuss, "Zanzalintinib in Osteosarcoma: Balancing Disease Control and Quality of Life".

Watch the full episode here: https://t.co/OBkSRRCnrL

#MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by Ram Rao, MD, PhD on OsteoBites to discuss, “Extracellular Matrix Degradation to Overcome Osteosarcoma Chemoresistance”.

Watch the full episode here: https://t.co/ydhuC29O6R

#MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

Thursday, we were joined by vAli Cihan, PhD on OsteoBites to discuss, "Targeting EPHA2 with dual-armored CAR T cells for immunotherapy in pediatric osteosarcoma".

Watch the full episode here: https://t.co/5nIlmA0fIO

#MIBAgents #MakeItBetter #osteosarcoma #OseoBites #podcast